Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

BACKGROUND: Human papillomavirus (HPV) types 16/18 drive oncogenesis for most patients with cervical, anal, and penile cancers. MEDI0457, a therapeutic DNA vaccine containing plasmids for E6 and E7 HPV-16/18 viral oncogenes and IL-12 adjuvant, is safe and provokes an immune response against E6/E7. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Van K, Jazaeri, Amir, Westin, Shannon N, Pettaway, Curtis, George, Solly, Huey, Ryan W, Grinsfelder, Michaela, Shafer, Aaron, Johnson, Benny, Vining, David, Guo, Ming, Fellman, Bryan, Frumovitz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Immuno-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322132/
https://www.ncbi.nlm.nih.gov/pubmed/37104874
http://dx.doi.org/10.1093/oncolo/oyad085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322132/
https://www.ncbi.nlm.nih.gov/pubmed/37104874
http://dx.doi.org/10.1093/oncolo/oyad085

Ejemplares similares